Phase 1 dose-escalation trial of AG-270 in multiple tumor types carrying an MTAP deletion
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2018
At a glance
- Drugs AG-270 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 08 Jan 2018 According to a company media release, company has got the FDA clearance of an IND application for AG-270, a MAT2A inhibitor, targeting MTAP-deleted tumors.
- 28 Dec 2017 New trial record
- 26 Dec 2017 According to a company media release, Agios expects to initiate the Phase 1 trial in the first quarter of 2018.